InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a research report issued to clients and investors on Wednesday. The brokerage set a “sell” rating on the stock.

InspireMD Stock Up 3.4 %

Shares of NYSE NSPR opened at $1.98 on Wednesday. InspireMD has a twelve month low of $1.00 and a twelve month high of $3.85. The company’s fifty day moving average is $2.41 and its 200-day moving average is $2.69. The stock has a market cap of $46.22 million, a price-to-earnings ratio of -1.83 and a beta of 0.84.

InspireMD (NYSE:NSPR) last announced its quarterly earnings data on Wednesday, March 6th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. The company had revenue of $1.76 million during the quarter, compared to the consensus estimate of $1.65 million. InspireMD had a negative net margin of 320.97% and a negative return on equity of 55.71%. During the same quarter last year, the firm posted ($0.60) EPS. On average, research analysts anticipate that InspireMD will post -0.61 EPS for the current fiscal year.

Institutional Investors Weigh In On InspireMD

An institutional investor recently bought a new position in InspireMD stock. McKinley Carter Wealth Services Inc. bought a new position in shares of InspireMD, Inc. (NYSE:NSPR) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 10,000 shares of the company’s stock, valued at approximately $28,000. 44.78% of the stock is currently owned by institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.